Molecular Partners Ag (MOLN) Receivables - Net (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Receivables - Net of $2953.7 for Q1 2026, down 33.23% year-over-year from $4423.4 in Q1 2025, and up 28.72% quarter-over-quarter from $2294.6 in Q4 2025.
Molecular Partners Ag (MOLN) Receivables - Net (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Receivables - Net for 7 consecutive years, with $2953.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 33.23% year-over-year to $2953.7; the TTM figure through Mar 2026 stood at $2953.7 (down 33.23% YoY), while the FY2025 annual figure was $2.3 million, down 13.24% from the prior year.
- Receivables - Net grew to $2953.7 in Q1 2026 per MOLN's latest filing, from $2294.6 in the prior quarter.
- Across five years, Receivables - Net topped out at $20.7 million in Q2 2023 and bottomed at $1791.3 in Q3 2022.
- Historically, Receivables - Net has averaged $3.9 million across 5 years, with a median of $3829.7 in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Net soared 108.15% — and 2025, when it tumbled 99.98%.
- Molecular Partners Ag's Receivables - Net stood at $1.1 million in 2022, then jumped by 108.15% to $2.2 million in 2023, then rose by 20.13% to $2.6 million in 2024, then sank by 99.91% to $2294.6 in 2025, then advanced by 28.72% to $2953.7 in 2026.
- Business Quant data shows MOLN's Receivables - Net at $2953.7 in Q1 2026, $2294.6 in Q4 2025, and $2629.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,953.71 |
| Mar 31, 2026 | 2,953.71 |
| Dec 31, 2025 | 2,294.65 |
| Dec 31, 2025 | 2,294.65 |
| Sep 30, 2025 | 2,628.98 |
| Sep 30, 2025 | 2,628.98 |
| Jun 30, 2025 | 4,354.44 |
| Jun 30, 2025 | 4,354.44 |
| Mar 31, 2025 | 4,423.42 |
| Mar 31, 2025 | 4,423.42 |
| Dec 31, 2024 | 2.64 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 3,829.66 |
| Sep 30, 2024 | 3,829.66 |
| Jun 30, 2024 | 20.57 Mn |
| Jun 30, 2024 | 20.57 Mn |
| Mar 31, 2024 | 3,642.12 |
| Mar 31, 2024 | 3,642.12 |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |